GlaxoSmithKline (GSK) has agreed to acquire U.S. oncology biotech firm Nuvalent for $10.6 billion, marking its largest deal in over a decade. The acquisition aims to bolster GSK’s cancer drug pipeline, particularly in lung cancer, and offset expected revenue drops from its HIV medication’s patent expiration in 2028. This move signals a strategic shift for GSK amid a broader uptick in biopharma M&A activity.
GSK Seals $10.6 Billion Deal for Nuvalent, Bolstering Oncology Pipeline
London, UK – Pharmaceutical giant GSK has announced an agreement to acquire U.S.-based Nuvalent Inc. for $10.6 billion in an all-cash deal, a move that significantly strengthens its oncology portfolio and marks the company's largest acquisition in over a decade. The acquisition aims to bolster GSK's revenue streams as its leading HIV medication faces exclusivity loss starting in 2028.
The deal values Nuvalent at approximately $124 per share, a 40% premium over its previous closing price. This strategic acquisition underscores GSK's commitment to expanding its presence in the oncology sector, particularly in lung cancer treatments. Nuvalent specializes in late-stage development biotech, focusing on specific genetic mutations in lung cancer.
Strategic Rationale and Pipeline Boost
GSK CEO Luke Miels highlighted the immediate sales growth opportunities presented by the acquisition. "The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer," Miels stated.
Nuvalent's key assets include two late-stage lung cancer treatments, neladalkib and zidesamtinib, both of which GSK believes have blockbuster potential. Neladalkib is currently under FDA review with a decision expected by November 27. Zidesamtinib, targeting ROS1-positive non-small cell lung cancer, is also undergoing FDA review. Analysts at CGS International project that these two drugs could generate combined annual revenues of $823 million by fiscal year 2029 if approved.
Market Context and Financial Implications
The acquisition comes amidst a surge in biopharma mergers and acquisitions, with global biotech deals reaching $106 billion across 201 transactions so far in 2026, according to PitchBook data. This trend is fueled by expiring patents, revitalized public markets, and a drive by major pharmaceutical companies to enhance their research and development pipelines.
While this acquisition represents a significant departure from GSK's recent focus on smaller deals, it aligns with its long-term strategy to mitigate revenue declines from its HIV drug portfolio. The company maintained its 2026 full-year guidance for core operating profit and core earnings-per-share growth, expecting the Nuvalent acquisition to contribute to revenue growth starting in 2027. This deal is GSK's second-largest acquisition historically, following its $20 billion asset swap with Novartis in 2014.
GSK shares experienced a slight dip of 2.6% in London trading following the announcement, while Nuvalent shares saw a nearly 39% surge in premarket trading.
This significant move signals GSK's ambitious plans to reshape its future growth trajectory and solidify its position as a leader in the pharmaceutical industry.
